URINE IODINE EXCRETION IN PATIENTS WITH PAPILLARY THYROID CANCER: EVALUATION OF THE RELATIONSHIP WITH THE PRESENCE OF A BRAF MUTATION

Basit Öğe Kaydı
dc.authoridCelik, Mehmet/0000-0001-7364-370X
dc.authoridyılmaz bülbül, buket/0000-0003-2651-0036
dc.authorwosidCelik, Mehmet/AAA-8773-2021
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidyılmaz bülbül, buket/JVZ-4676-2024
dc.contributor.authorCelik, Mehmet
dc.contributor.authorGuldiken, Sibel
dc.contributor.authorSalt, Semra Ayturk
dc.contributor.authorBulbul, Buket Yilmaz
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorCan, Nuray
dc.contributor.authorTastekin, Ebru
dc.date.accessioned2024-06-12T11:12:02Z
dc.date.available2024-06-12T11:12:02Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIodine is an essential element for the production of thyroid hormones. In recent years, it has been suggested that excessive consumption of iodine may play a role in the pathogenesis of papillary thyroid cancer (PTC). In addition, studies have suggested that high iodine consumption is an important risk factor for the formation of a BRAF mutation in the thyroid gland. A prospectively designed study included 132 cases scheduled for thyroidectomy for various reasons. Urine iodine levels of all patients were examined before the operation. The iodine excretion levels of the patients were grouped according to the median urinary iodine concentration determined in community screenings (those with <100 mu g L-1 low iodine excretion, those with 100-199 mu g L-1 normal iodine excretion, those with 200-299 mu g L-1 high iodine excretion). Patients were divided into 3 groups according to the post-operative pathology results. As a result of thyroid histopathology, benign (n: 44), PTC (n: 88) (BRAF (+): 44 and BRAF (-): 44) cases were included in the study. BRAF mutations in patients diagnosed with PTC were evaluated using the Real Time PCR Melting Curve Analyzer method. The relationship between urinary iodine excretion levels and clinical, histopathological and BRAF positivity was examined. In our study, no difference was found in urinary iodine excretion between patients with and without PTC. Hashimoto's thyroiditis was observed more frequently in patients with PTC (p=0.023). In addition, Hashimoto's thyroiditis was statistically more frequently detected in the BRAF (-) group compared to the BRAF (+) and control group (p=0.034). Despite studies suggesting that high iodine consumption is important in PTC pathogenesis, we did not find a relationship between the mutation and iodine consumption, which plays an important role in the development of PTC.en_US
dc.identifier.doi10.5601/jelem.2020.25.1.1984
dc.identifier.endpage1028en_US
dc.identifier.issn1644-2296
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85090815780en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage1019en_US
dc.identifier.urihttps://doi.org/10.5601/jelem.2020.25.1.1984
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23013
dc.identifier.volume25en_US
dc.identifier.wosWOS:000580459000004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherPolish Society Magnesium Researchen_US
dc.relation.ispartofJournal Of Elementologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPapillary Thyroid Canceren_US
dc.subjectBRAF Mutationen_US
dc.subjectUrine Iodine Excretionen_US
dc.subjectRisken_US
dc.subjectEpidemiologyen_US
dc.subjectAssociationen_US
dc.subjectCarcinomasen_US
dc.subjectGeneticsen_US
dc.subjectAreaen_US
dc.titleURINE IODINE EXCRETION IN PATIENTS WITH PAPILLARY THYROID CANCER: EVALUATION OF THE RELATIONSHIP WITH THE PRESENCE OF A BRAF MUTATIONen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu